Defunct Company
Total Trials
15
As Lead Sponsor
1
As Collaborator
14
Total Enrollment
2,239
NCT01430507
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Phase: Phase 2
Role: Collaborator
Start: Sep 30, 2011
Completion: Dec 31, 2012
NCT01436890
A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma
Start: Oct 31, 2011
Completion: Apr 30, 2013
NCT01726413
A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).
Start: Nov 30, 2012
Completion: Sep 30, 2014
NCT02179645
GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers
Phase: Phase 1
Start: May 31, 2014
Completion: Dec 31, 2014
NCT02235727
Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects
Start: Jul 31, 2014
Completion: Nov 30, 2016
NCT02361034
To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects
Role: Lead Sponsor
Start: Jan 31, 2015
Completion: Sep 30, 2015
NCT02683928
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
Start: Mar 31, 2016
Completion: Jun 30, 2017
NCT02829372
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
Start: May 31, 2016
Completion: May 31, 2019
NCT03309111
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
Start: Oct 25, 2017
Completion: Dec 15, 2023
NCT03568162
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Start: May 31, 2018
Completion: Aug 3, 2021
NCT05286944
Mobile Phone Daily Alarm To Improve Compliance Of Intranasal Corticosteroid Among Allergic Rhinitis Patients.
Phase: N/A
Start: Jan 19, 2020
Completion: Jun 22, 2022
NCT03983395
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
Phase: Phase 1/2
Start: Apr 8, 2020
Completion: Jul 24, 2020
NCT05146206
Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
Start: Nov 8, 2021
Completion: Feb 27, 2022
NCT05129306
Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes
Start: Nov 17, 2021
Completion: Mar 14, 2022